[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-risk-factor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-risk-factor":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,48,70,95,129,159,182,230,266,295,316,348,375,410,436,466,492,518,553,603],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100210443","gut-flora-metabolite-reduction-after-dietary-intervention-grady-100210443",false,"NCT02016430","Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)","GRADY","Inclusion Criteria:\n\nCohort 1 Inclusion criteria:\n\n* Men and women age 18 years or above.\n* Elevated TMAO metabolizers (\\>5 µM) based on screening test and\u002For eGFR \\\u003C 60 at most recent measurement.\n* Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study.\n* Willing to sign the consent form and follow the study protocol, which includes a 12-week dietary modification.\n\nCohort 2 Inclusion criteria:\n\n* Men and women age 18 years or above.\n* Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study.\n* Willing to sign the consent form and follow the study protocol.\n* eGFR values ranging from 16-59\n\nCohort 3 Inclusion criteria:\n\n* Men and women age 18 years or above.\n* Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study.\n* Willing to sign the consent form and follow the study protocol.\n\nExclusion Criteria (all cohorts):\n\n* Significant chronic illness or end-organ dysfunction, including known history of uncompensated heart failure, renal failure, pulmonary disease, hematologic diseases.\n* Active infection or received antibiotics within 2 months of study enrollment\n* Use of over-the-counter probiotic within past month, or ingestion of yogurt within past 7 days\n* Having undergone bariatric procedures or surgeries such as gastric banding or bypass.\n* Pregnancy.\n* Any condition which, in the judgment of the Investigator, would place a patient at undue risk by being enrolled in the trial, or cause inability to comply with the trial",true,"ALL","18 Years",{"count":20,"type":21},170,"ESTIMATED","INTERVENTIONAL",[24],"NA","Our group has recently identified the association between gut-flora-mediated carnitine and phosphatidylcholine metabolism, specifically trimethylamine-N-oxide (TMAO), and cardiovascular risk. This study investigates the ability for dietary intervention to modulate TMAO levels.",[27,28],"Dietary Modification","Cardiovascular Risk Factor",[30,31,32,33,34],"TMAO","Gut Flora","Dietary Intervention","Choline","Carnitine","RECRUITING","2026-06-23",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":41,"type":39},"2014-04-04",{"date":43,"type":21},"2026-12",{"name":45,"class":46},"The Cleveland Clinic","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":47},"100392357","biomedical-research-informatics-centre-for-cardiovascular-sciences-the-briccs-study-100392357","NCT04388943","Biomedical Research Informatics Centre for Cardiovascular Sciences (The BRICCS Study)","Inclusion Criteria:\n\n* All outpatients and inpatients with cardiovascular disease, of either gender\n* Aged 18-90 years old\n* Examples of conditions include: coronary artery disease, heart failure, heart attacks (myocardial infarction), valve disease, cardiac surgery, dysrhythmias (including atrial fibrillation), aneurysms, embolism, strokes, peripheral vascular disease, hypertension (and its complications, such as left ventricular hypertrophy) or those presenting with chest pain\n* Healthy volunteers\n* Aged 18-90 years old\n* From the community without cardiovascular or other diseases\n\nExclusion Criteria:\n\n* Any patient who is unable to give consent\n* Any patient with non-cardiovascular comorbidity likely to cause death within 6 months\n* Patients know to be infected with HIV, Hepatitis B or any other agent posing an infection risk from unfixed material","90 Years",{"count":56,"type":21},9500,"OBSERVATIONAL","This project will examine the diagnosis and prognosis of patients with cardiovascular disease in hospital in- and outpatients and compare their characteristics with normal controls from the community. The cardiovascular diseases studied include coronary artery disease, heart failure, heart attacks, valve disease, cardiac surgery, dysrhythmias, aneurysms, embolism, strokes, peripheral vascular disease and hypertension. Current methods for diagnosis and predicting outcome in patients are limited and may lack accuracy. This study will collect clinical details, and blood and urine samples from patients for analysis of proteins, chemicals and genetic biomarkers which will enable an examination of the pathological mechanisms involved in cardiovascular disease. The data will also be used to improve diagnosis and also improve prediction of outcome in patients (future clinical events such as death, further hospitalisation with cardiovascular disease and the effects of any therapy given to the patients). In this way, we can develop accurate ways of assessing a patient's condition and how it could be effectively managed. The study will last for 20 years.",[60,28],"Cardiovascular Diseases","2026-06-10",{"date":63,"type":39},"2026-06-11",{"date":65,"type":39},"2010-06-17",{"date":67,"type":21},"2027-03-31",{"name":69,"class":46},"University Hospitals, Leicester",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":47},"100370272","mechanisms-underlying-the-protective-vascular-effects-of-dietary-potassium-in-humans-100370272","NCT04101188","Mechanisms Underlying the Protective Vascular Effects of Dietary Potassium in Humans","Inclusion Criteria:\n\n* healthy\n* normal blood pressure\n* normal resting ECG\n\nExclusion Criteria:\n\n* hypertension\n* history of heart disease\n* diabetes\n* kidney disease\n* obese (BMI ≥30)\n* significant weight changes in the last 6 months\n* use of tobacco products\n* pregnant\n* on a special diet (gluten free; vegan)\n* take any medications for the above conditions\n* endurance trained athletes","45 Years",{"count":78,"type":21},90,[24],"Americans continue to consume high amounts of sodium. Potassium is notable for its blood pressure lowering effects but less is known regarding its effect on the vasculature. This investigation seeks to determine the role of dietary potassium on the vasculature in the presence of a high sodium diet in salt-resistant adults.",[28],[83,84,85],"Dietary Potassium","Dietary Sodium","Vascular Health","2026-03-02",{"date":88,"type":39},"2026-03-04",{"date":90,"type":39},"2020-01-16",{"date":92,"type":21},"2026-07-31",{"name":94,"class":46},"University of Delaware",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":105,"studyType":57,"phases":4,"briefSummary":106,"conditions":107,"keywords":112,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":47},"100322647","biomechanical-precision-medicine-registry-for-patients-with-and-without-heart-failure-100322647","NCT03480633","Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure","Preserved vs. Reduced Ejection Fraction Biomarker Registry and Precision Medicine Database for Ambulatory Heart Failure Patients (PREFER-HF) Study","PREFER-HF","Inclusion criteria for patients with HF:\n\n* 18 years and older\n* History of clinical symptoms consistent with HF and at least one of the following supporting evidence of HF:\n\n  * NT-proBNP \\> 125 pg\u002FmL\n  * BNP \\> 35 pg\u002FmL\n  * Capillary wedge pressure ≥ 15 mmHg on right heart catheterization or CI \\\u003C2.8 L\u002Fmin\u002Fm2\n  * LVEDP ≥ 15 mmHg\n  * Radiographic evidence of pulmonary edema\n  * Improvement in symptoms with diuretic initiation of increase\n  * CPET evidence of cardiac etiology of symptoms\n\nHFpEF: LVEF ≥ 50% HFrEF: LVEF \\\u003C50%\n\nExclusion criteria (for all patients, including both those with HFpEF and HFrEF):\n\n\\- End stage renal disease on dialysis",{"count":104,"type":21},3000,"50 Months","In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure.",[108,109,110,111,28],"Heart Failure With Normal Ejection Fraction","Heart Failure With Reduced Ejection Fraction","Heart Failure, Right Sided","Heart Failure With Mid Range Ejection Fraction",[113,114,115,116,117,118,119],"Heart failure","Precision medicine","High risk patients","Pathophysiology","Bioregistry","Biomarkers","Heart failure etiology","2025-12-02",{"date":122,"type":39},"2025-12-09",{"date":124,"type":39},"2016-04-07",{"date":126,"type":21},"2027-10-06",{"name":128,"class":46},"Massachusetts General Hospital",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":47},"100595320","phase-2-reducing-systemic-inflammation-in-people-on-antiretroviral-therapy-100595320","NCT07030920","Reducing Systemic Inflammation in People on Antiretroviral Therapy","RESTART","Inclusion Criteria:\n\n* 40 years or older, or have lived with HIV for 25 years or more, any sex;\n* Undetectable HIV viral load (defined as last viral load measurement less than 50 copies\u002Fml within the last 6 months);\n* Presence of at least one cardiovascular risk factor among the following: longstanding HIV infection (25 years or more), hypertension, diabetes, past or present smoking, dyslipidemia, family history of early onset CVD in a first-degree relative (defined as younger than 55 in males or younger than 65 in females (80)), known previous cardiovascular disease (defined as past myocardial infarction, coronary revascularization, stroke, or coronary artery atherosclerosis with \\>= 50% stenosis demonstrated on coronary angiography or CCTA);\n* Participants with past cardiovascular disease must be in a stable clinical condition as judged by the study clinicians;\n* Past cardiovascular events are defined as having occurred at least 3 months before screening;\n* Evidence of detectable plasmatic sgp120 levels at any point in the past year, using the assay described priorly and performed at CRCHUM in Dr Andrés Finzi's laboratory.\n\nExclusion Criteria:\n\n* Known allergy to study drug;\n* Concomitant treatment with strong cytochrome P450 (CYP3A) inducers, including but not limited to: carbamazepine, phenytoin (anticonvulsants), mitotane (antineoplastic), enzalutamide (androgen receptor inhibitor), rifampicin (antimycobacterial) and St John's wort (Hypericum perforatum, herbal supplement);\n* Planning to become pregnant, pregnant, or breastfeeding (as requested per product monography (55)). Females of childbearing potential must have a negative pregnancy test at baseline visit, and follow contraception requirements throughout the treatment;\n* Contraindication for CT scan use (estimated glomerular filtration rate \\[eGFR\\] less than 40ml\u002Fmin using the Modification of Diet in Renal Diseases \\[MDRD\\] formula or iodine allergy);\n* Elevated risk of prior ionizing radiation exposure outside clinical care exceeding 10 mSV over 3 years, per the investigator's judgement (eg. a participant with occupational ionizing radiation exposure, prior participation in clinical trials with multiple CT scans)\n* Confirmed uncorrected QT value \\>500ms or confirmed QTcF \\>470 msec for women and \\>450 msec for men;\n* Acquired\u002F congenital long QT syndrome;\n* Current or anticipated treatment with any of the following medications: amiodarone, disopyramide, dofetilide, ibutilide, procainamide, sotalol, and quinidine;\n* Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy (INR \\> 2.0), hypoalbuminemia (\\\u003C30 mg\u002Fml), untreated esophageal or gastric varices, or persistently elevated bilirubinemia (\\>1.5x upper limit of normal \\[ULN\\]), known biliary abnormalities (except Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment);\n* ALT \\>=5 times the ULN, OR ALT \\>=3xULN and bilirubin \\>=1.5xULN with \\>35% direct bilirubin;\n* History of liver cirrhosis with CHILD-PUGH classification C;\n* Inability to provide informed consent;\n* Life expectancy of less than 36 months;\n* Inability to present to study visits;\n* Participation in another interventional trial;\n* Known Congestive heart failure with NYHA class 3 or 4.",{"count":137,"type":21},150,[139],"PHASE2","This randomized, open-label clinical trial will evaluate whether adding fostemsavir to current antiretroviral therapy can reduce the risk of cardiovascular disease in people with well-controlled HIV. Researchers will compare imaging, clinical and biomarker outcomes between participants who receive fostemsavir in addition to their existing treatment and those who continue with standard care alone.",[142,28],"Human Immunodeficiency Virus (HIV)",[144,145,146,147,148,149,28],"Fostemsavir","Rukobia","sgp120","Perivascular fat attenuation index (P-FAI)","uncalcified plaque volume","Systemic inflammation","2025-11-17",{"date":152,"type":39},"2025-11-19",{"date":154,"type":39},"2025-09-30",{"date":156,"type":21},"2029-01",{"name":158,"class":46},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":166,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":47},"100402630","diurnal-bp-patterns-in-those-at-increased-risk-of-cvd-100402630","NCT04522765","Diurnal BP Patterns in Those at Increased Risk of CVD","Diurnal Blood Pressure and Arterial Stiffness Patterns in Those at Increased Risk of Cardiovascular Disease","Inclusion Criteria:\n\n* Patients will be eligible to take part in the study if they attend NHS Lothian inpatient or outpatient services and can be classified as being at increased risk of CVD. This will include, but is not limited to, the following subgroups:\n\n  1. CKD as defined by the Kidney Disease Outcome Quality Initiative (K\u002FDOQI) classification\n  2. AKI as defined by the Kidney Disease Improving Global Outcomes (KDIGO) classification\n  3. Small vessel vasculitis\n  4. Kidney transplant recipient\n  5. Kidney donor We will also recruit a healthy control group from the community.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years and \\>90 years\n2. Lack of ability to provide informed consent",{"count":167,"type":21},120,"In health, blood pressure (BP) falls at night by \\>10% compared with day-time values. This natural dipping pattern is important as without it there is an increased risk of cardiovascular disease (CVD). Recent evidence suggests that chronotherapy (taking anti-hypertensive medication at bedtime instead of in the morning) may enhance nocturnal BP dipping and reduce the risk of CVD events. There is therefore an urgent need to characterise diurnal BP patterns in patients who may be at risk of reduced nocturnal dipping in order to maximise protective therapy in all those who would benefit. Similarly, it has previously been demonstrated that increased arterial stiffness is associated with increased CVD risk, however little is known about whether loss of diurnal variations in arterial stiffness confer addition risk. Kidney disease is independently associated with increased CVD events, but the exact makeup of this risk is not clear. Within this heterogenous cohort several very distinct groups exist including those with acute kidney injury (AKI), chronic kidney disease (CKD), inflammatory conditions like small vessel vasculitis (SVV), and those who have either donated or received a kidney transplant. Diurnal BP and arterial stiffness patterns within these patient groups are not well characterised. The investigators will recruit patients at increased risk of CVD from the Royal Infirmary of Edinburgh Renal and Vasculitis Clinics. Participants will undergo 24-hour ambulatory BP and arterial stiffness measurement in conjunction with day- and night-time blood and urine sampling on two separate occasions. This study aims to characterise diurnal patterns of BP and arterial stiffness in patients at increased risk of CVD and compare findings with healthy controls. In doing so, the investigators aim to allow more targeted CVD risk reduction strategies and improve long-term patient outcomes.",[28,170,171,172],"Blood Pressure","Arterial Stiffness","Chronic Kidney Diseases","2025-09-18",{"date":175,"type":39},"2025-09-23",{"date":177,"type":39},"2020-03-17",{"date":179,"type":21},"2026-12-31",{"name":181,"class":46},"University of Edinburgh",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":192,"conditions":193,"keywords":216,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":47},"100435439","prevalence-and-risk-factors-associated-with-cardiac-comorbidity-in-psoriasis-100435439","NCT04950218","Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis","PSOCADIA: Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis","PSOCADIA","Inclusion Criteria:\n\n* Patients 18 years or older with a diagnosis of psoriasis will be invited to participate\n\nExclusion Criteria:\n\n* Patients not able to cooperate to the study\n* Patients unable understand and sign informed consent",{"count":191,"type":21},1000,"In a prospective cohort study (n = 1.000), the investigators aim to investigate the correlation between cardiac biomarkers and advanced echocardiography and determine whether these are prognostic markers of heart disease in patients suffering from psoriasis.",[194,60,28,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215],"Psoriasis","Cardiovascular Pathology","Psoriasis Vulgaris","Psoriatic Nail","Psoriasis Face","Psoriasis Guttate","Psoriasis Gyrata","Psoriasis Diffusa","Psoriasis Palmaris","Psoriasis Annularis","Psoriasis Circinata","Psoriasis Plantaris","Psoriasis Universalis","Psoriasis Geographica","Left Ventricular Dysfunction","Myocardial Infarction","Myocardial Ischemia","Heart Failure","Stroke","Heart Diseases","Heart Failure, Systolic","Heart Failure, Diastolic",[194,217,218,118,219,220],"Echocardiography","Advanced echocardiography","Mortality","Cardiovascular mortality","2025-09-09",{"date":223,"type":39},"2025-09-15",{"date":225,"type":39},"2021-09-01",{"date":227,"type":21},"2034-10-01",{"name":229,"class":46},"Herlev and Gentofte Hospital",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":237,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":246,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100602531","syntrillo-telehealth-stroke-risk-reduction-study-100602531","NCT07124728","Syntrillo Telehealth Stroke Risk Reduction Study","Impact of Syntrillo's Telehealth Service on Stroke Risk Factor Reduction in At-risk Patients","Inclusion Criteria:\n\n* Age greater than or equal to 30\n* Diagnosis of hypertension\n* One or more of the following:\n* Dtrial fibrillation\n* Diabetes\n* Chronic kidney disease (stage 2+)\n* Obesity (class 2+)\n* Obstructive sleep apnea\n* Coronary artery disease\n* Hyperlipidemia\n* Carotid stenosis (greater than or equal to 50%)\n* Congestive heart failure\n\nExclusion Criteria:\n\n* History of stroke or TIA\n* Inability to consent or understand study\n* Residence in long-term acute care facility\n* Inability to ambulate independently\n* Non-English speaking\n* No internet access\n* Not residing in Virginia\n* Pregnancy or suspected pregnancy","30 Years",{"count":239,"type":21},68,[24],"A prospective, single-arm, open-label study evaluating the impact of Syntrillo's telehealth program on stroke risk factors, particularly blood pressure, among 68 high-risk patients. The 6-month intervention includes personalized remote care with blood pressure monitoring, wearable tracking, and multidisciplinary telehealth visits.",[243,244,245,28],"Hypertension","Hypertension (HTN)","Stroke Prevention",[247,248,249,250,251,252,253,254,255],"stroke prevention","telehealth","telemedicine","blood pressure","remote patient monitoring","digital health","heart rate variability","inflammation","hypertension","NOT_YET_RECRUITING","2025-08-08",{"date":259,"type":39},"2025-08-15",{"date":261,"type":21},"2025-08",{"date":263,"type":21},"2026-05",{"name":265,"class":46},"Syntrillo, Inc",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":17,"minAge":274,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":22,"phases":278,"briefSummary":279,"conditions":280,"keywords":281,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":293,"locationsCount":4},"100600336","afterschool-rx-20-prescriptions-to-afterschool-care-for-pediatric-cardiovascular-risk-reduction-100600336","NCT07096167","Afterschool Rx 2.0: Prescriptions to Afterschool Care for Pediatric Cardiovascular Risk Reduction","Advancing Pediatric Cardiovascular Health Through Afterschool Care: A Preliminary Randomized Controlled Trial","ARx","Inclusion Criteria:\n\n* A child must be entering 1st-4th grade when recruited (i.e., 5-11 years old)\n* A child must have one or more cardiovascular risk factors as identified by a clinical care provider (i.e., obesity, hypertension, hyperglycemia, hyperlipidemia)\n* Attend an elementary school patterned with a participating afterschool program\n* Belong to a family at or below 250% of the federal poverty level\n* The participating parent\u002Fguardian must have a phone that accepts text messages\n\nExclusion Criteria:\n\n* If the child does not meet the inclusion criteria for attending the participating afterschool programs (e.g., children that require specially trained staff to safely provide care),\n* If the child is pregnant\n* If it is unsafe for the child to participate in any of the study measures as determined by their clinical care provider (i.e., can not safely complete a 6-min walk test or finger stick)","5 Years","11 Years",{"count":277,"type":21},48,[24],"The goal of this clinical trial is to learn if \"prescribing\" afterschool care to children at risk for poor heart health later in life increases their physical activity and improves their heart health. 'Prescriptions' will be provided by pediatricians at participating Federally Qualified Health Centers and vouchers to existing afterschool programs (e.g., YMCA, Boys and Girls Clubs) will be provided by the research study. The main questions this study aims to answer are:\n\nCan afterschool care providers and health care providers easily offer and keep using the voucher program?\n\nWill families use the voucher? Do they go to afterschool care regularly, and do the families who use them represent a wide range or backgrounds?\n\nDoes going to afterschool care help children be more physical activity?\n\nDoes going to afterschool care improve heart health?\n\nResearchers will compare two randomly assigned time periods; one semester when families get the voucher and one semester where they do not. They will look at whether use of the afterschool care voucher leads to more physical activity and improved heart health.",[28],[282,283,284,285,286],"cardiovascular","out-of-school time","afterschool care","pediatric","physical activity","2025-07-30",{"date":289,"type":39},"2025-08-03",{"date":261,"type":21},{"date":292,"type":21},"2028-05",{"name":294,"class":46},"Augusta University",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":302,"enrollmentInfo":303,"targetDuration":274,"studyType":57,"phases":4,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":47},"100368273","community-benefit-of-no-charge-calcium-score-screening-program-100368273","NCT04075162","Community Benefit of No-charge Calcium Score Screening Program","CLARIFY","Inclusion Criteria:\n\n* Received Coronary Artery Calcium (CAC) CT scan at University Hospitals starting in January 1, 2014.\n\nExclusion Criteria:\n\n\\-","100 Years",{"count":304,"type":21},77000,"Current approaches in primary prevention for cardiovascular disease are based on probabilistic approaches to estimate risk, using many of the widely available cardiovascular risks scores, with over 100 such scoring systems currently available throughout the world. The rationale for this practice is to select those individuals at greatest risk for more intense targets, reduce risk of treatment to those at minimal risk, and to maximize the cost-effectiveness of treatment. A recent Cochrane Systematic Review assessed the practice of using risk scores to select individuals for the primary prevention of cardiovascular disease. 3 The principal finding of the systematic review was that there was little or no effect of providing clinicians with cardiovascular risk scores when compared to standard of care (5.4% versus 5.3%; relative risk 1.01, 95% confidence intervals 0.95 to 1.08). The authors concluded that there is major uncertainty whether current strategies for providing risk scores and called for further research to address this concern. Extent of coronary artery calcium (CAC) is a strong risk marker for coronary events, with evidence mainly derived from observational studies and from prospective non-randomized studies. CAC, although endorsed for intermediate risk patients, is not widely adopted due to barriers in reimbursement. The cost of the test ranges between 100 and 300 USD in the United States, which may have limited the wide adoption of the test. Whether reducing the cost burden for CAC increases utilization for routine screening and its influence on physician practices and downstream testing is largely unknown. University Hospitals started offering low charge CAC (99$) since 2014. In 2017, University Hospitals started offering CAC for no charge for patients to improve access to this test, which has not traditionally been covered by insurance companies. The impact of no-charge CAC has never been studied.",[28],"2025-07-15",{"date":309,"type":39},"2025-07-18",{"date":311,"type":39},"2014-01",{"date":313,"type":21},"2032-12",{"name":315,"class":46},"University Hospitals Cleveland Medical Center",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":16,"sex":324,"minAge":76,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":22,"phases":328,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":47},"100598372","abertay-tea-for-cardiovascular-health-during-menopause-100598372","NCT07070635","Abertay Tea for Cardiovascular Health During Menopause","The Effect of the Fermented Seaweed Enriched Abertay Tea on Vascular Function and Markers of Cardiovascular Risk During Menopause","AberTeaM","Inclusion Criteria:\n\n* Postmenopausal status: no menstrual period over the last 12 months\n* Regular tea drinkers (at least once a week), willingness to consume 3 cups of English breakfast tea per day for 8 weeks\n* BMI between 18.5 and 39.99 kg\u002Fm2\n\nExclusion Criteria:\n\n* Reported history of CVD (myocardial infarction, angina, venous thrombosis, stroke, dyslipidemia), diabetes (or fasting glucose ≥ 6.1 mmol\u002FL), kidney, liver or bowel disease.\n* Recent history of cancer (\\\u003C1y)\n* History indicative of a congenital or acquired platelet or haemostatic defect.\n* Presence of gastrointestinal disorder or use of drug, which is likely to alter gastrointestinal motility or nutrient absorption.\n* Recent use of hypolipidaemic, antiplatelet or antithrombotic medications\n* Impairment of thyroid function\n* Current smokers or vapers\n* Current self-reported weekly alcohol intake exceeding 14 units\n* Current or recent use of hormone replacement therapy (\\\u003C3 months)\n* Recent participation in another clinical trial (\\\u003C3 months)\n* Allergy or intolerance to crustaceans or iodine","FEMALE","74 Years",{"count":327,"type":21},44,[24],"The regular consumption of seaweed, as observed in Japan, is associated to a reduced cardiovascular risk and prolonged life expectancy. Interventional studies have shown that brown seaweed consumption can reduce blood pressure, improve glycaemic control and lipoprotein profiles, although this varies with population, dose, duration and the type of seaweed. Brown seaweed appears the most promising to improve cardiovascular risk, due to the presence of specific antioxidants (polyphenols called phlorotannins), pigments (fucoxanthin) and fibre (alginate, fucoidan).\n\nWomen see their cardiovascular risk greatly increased when they reach menopause, and seaweed consumption may provide benefits for this population. In the UK, 98% of UK residents drink tea daily (Source UKTIA), with English breakfast tea being the most popular. Providing a tea enriched with beneficial compounds has the potential to improve cardiovascular health in a wide range of the population, including postmenopausal women. Abertay university (Dundee, UK) has recently developed an English Breakfast tea enriched with fermented seaweed, which was found to taste like English breakfast tea. We hypothesise that the consumption of 3 cups a day of the Abertay-developed Tea (AberTea) for 8 weeks, with each tea bag containing 1g of fermented seaweed, will improve vascular function and cardiovascular risk factors in postmenopausal women.",[28,331],"Vascular Function",[333,334,335,336,337,338],"seaweed","fermented","menopause","vascular function","cardiovascular risk","continuous non invasive arterial pressure","2025-07-08",{"date":341,"type":39},"2025-07-17",{"date":343,"type":39},"2025-06-16",{"date":345,"type":21},"2025-11",{"name":347,"class":46},"Abertay University",{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":16,"sex":17,"minAge":355,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":47},"100424225","sleep-duration-and-cardiovascular-health-100424225","NCT04804124","Sleep Duration and Cardiovascular Health","Goldilocks","Inclusion Criteria:\n\n* Men and women ages 25-65y\n* Lean and overweight (BMI 18.5-40 kg\u002Fm2)\n* No acute, chronic, or debilitating medical conditions\n* No prescription\u002Fnon-prescription medications or drugs of abuse\n* Current non-smoker (tobacco and marijuana)\n* Persons who fit all the above criteria and are suitable based on a medical history and health habits questionnaire, and additional sleep and health profiling questionnaires may be eligible to participate.\n\nExclusion Criteria:\n\n* Persons with any acute, chronic, or debilitating medical condition except pre-hypertension will be excluded.\n* Persons with any symptoms of acute or active illness (e.g. fever, leukocytosis) will be excluded.\n* Persons with a history of severe psychiatric illness or psychiatric disorders will be excluded.\n* Persons with a history of regular night\u002For rotating shift work in the past year, or who have traveled more than three time zones during the one month prior to the study will be excluded.\n* Pregnant women, decisionally impaired adults, and prisoners will be excluded.","25 Years","65 Years",{"count":358,"type":21},24,[24],"This is a cross-sectional study with an optional intervention that will examine how extreme sleep durations relate to cardiovascular health, physical activity, and sleep quality by studying three groups of participants: short sleepers (≤ 6 hrs), long sleepers (≥ 9 hrs), and average duration sleepers (7-8 hrs). The optional intervention asks participants to maintain an 8-hour per night regular sleep schedule for one week.",[362,28],"Sleep",[282,364,365],"sleep duration","vascular endothelial function","2025-05-09",{"date":368,"type":39},"2025-05-14",{"date":370,"type":39},"2021-06-09",{"date":372,"type":21},"2026-03-15",{"name":374,"class":46},"Oregon Health and Science University",{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":17,"minAge":383,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":22,"phases":387,"briefSummary":388,"conditions":389,"keywords":397,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":47},"100585834","preventative-screening-and-health-coaching-in-a-food-insecure-population-100585834","NCT06907524","Preventative Screening and Health Coaching in a Food Insecure Population","Community-Based Preventative Cardiometabolic Screening and Health Coaching- A Prospective Study","HEALTHCOACH","Inclusion:\n\nPatient is a participant at a CHI sponsored, community screening event Patient provides informed consent and willingness to participate for the duration of the study English or Spanish speaking Age 40-75 years old At least 1 cardiometabolic risk factor at suboptimal level\n\nDefined as one or more of the following at initial screening:\n\nBlood Pressure (BP):\n\nSystolic BP greater than 130mmHg and\u002For diastolic BP greater than 80mmHg. Obesity: body mass index (BMI) greater than 30 〖kg\u002Fm〗\\^2\n\nDyslipidemia:\n\nTotal cholesterol greater than 200 mg\u002FdL Triglycerides greater than 150 mg\u002FdL Low density lipoprotein (LDL) greater than 130 mg\u002FdL High density lipoprotein (HDL) less than 40 mg\u002FdL in men or less than 50 mg\u002FdL in women Hemoglobin A1c greater than or equal to 5.7% 10-year ASCVD score greater than 5% Access to a telehealth compatible device\n\nExclusion:\n\nAdults unable to provide informed consent or unwilling to participate for study duration Speaks language other than English or Spanish Younger than 40 years old or older than 75 years old All cardiometabolic risk factors at optimal levels No telehealth compatible device Pregnant patients","40 Years","75 Years",{"count":386,"type":21},200,[24],"The goal of this longitudinal study is to investigate the role of virtual health coaching on mitigation of cardiometabolic disease risk in an underserved, food insecure population. The main questions it aims to answer are:\n\n* Does longitudinal, individualized health coaching directed at lifestyle modification reduce patient 10-year risk of heart attack or stroke?\n* Does longitudinal, individualized health coaching directed at lifestyle modification reduce rates of hypertension, hyperlipidemia, and diabetes?\n* Does longitudinal, individualized health coaching directed at lifestyle modification improve accessibility to healthcare?\n\nResearchers will investigate the effects of regularly scheduled health coaching sessions on composite cardiometabolic risk profile as well as individual modifiable cardiovascular risk factors.\n\nParticipants will:\n\n* Participate in in-person cardiovascular screening, occuring at the time of enrollment, months 3 and 6.\n* Engage in virtual health coaching sessions to talk about diet, exercise, weight loss, blood pressure and diabetes control, and accessibility to healthcare\n* Keep a log of their blood pressure",[390,391,28,392,243,393,394,395,396],"Cardiovascular Disease Prevention","Cardiometabolic Diseases","Cardiovascular Risk Score","Hyperlipidemia","Diabetes","Lifestyle Modification","Health Coaching",[390,398,243,393,394,395,396,392,399,28,400],"Cardiometabolic Disease Screening","Atherosclerotic Cardiovascular Disease Risk Score","Cardiometabolic Disease","2025-03-26",{"date":403,"type":39},"2025-04-02",{"date":405,"type":21},"2025-04-01",{"date":407,"type":21},"2027-07-01",{"name":409,"class":46},"Rush University Medical Center",{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":417,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":420,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":47},"100306063","phase-4-intervention-for-high-normal-blood-pressure-in-adults-with-type-2-diabetes-100306063","NCT03264352","Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes","IPAD","Inclusion Criteria:\n\n* irrespective of sex;\n* aged between 45 and 79 years;\n* with office-measured seated BP 120-139 mm Hg systolic and below 90 mm Hg diastolic;\n* diagnosed of type 2 diabetes mellitus (T2DM), currently on diabetic therapy;\n* informed consent provided and long-term follow-up possible\n\nExclusion Criteria:\n\n* poor control of blood glucose, HbA1c \\> 10.0%\n* administration of any antihypertensive medications within 1 month;\n* a history of hypoglycemic coma \u002F seizure;\n* confirmed diagnosis of type 1 diabetes mellitus;\n* alanine-aminotransferase (ALT) or aspartate-aminotransferase (AST) over three times the upper limit of normal;\n* estimated glomerular filtration rate \\\u003C 45 ml\u002Fmin\u002F1.73m2;\n* a history of congestive heart failure with left ventricular ejection fraction \\\u003C 40%;\n* coronary artery disease requiring RAS blockers for secondary prevention;\n* acute on-set of stroke within 6 months prior to randomization;\n* a ratio of urinary albumin (in mg\u002FL) to urinary creatinine (in g\u002FL) (ACR) ≥ 300 mg\u002Fg;\n* known contraindications for the active study medications;\n* a history of psychological or mental disorder;\n* pregnancy or currently planning to have babies or lactation;\n* severe diseases such as severe heart diseases;\n* an expected residual life span less than 3 years;\n* a malignancy that clinical investigators consider as unsuitable to participate;\n* currently participating in another clinical trial.","79 Years",{"count":419,"type":21},11414,[421],"PHASE4","Lowering of blood pressure (BP) in high-risk hypertensive individuals reduces major adverse cardiovascular and cerebrovascular events. Diabetic patients with hypertension benefit from BP lowering treatment. The present trial, IPAD in brief, is a randomized, open-label, parallel-designed, multicenter study involving nearly 12,000 patients to be recruited and to be followed up for a median of four years. IPAD tests the hypothesis that antihypertensive medications in adults with type 2 diabetes, whose seated BP 120-139 mm Hg systolic and below 90 mm Hg diastolic, results in 20% difference in the incidence of major adverse cardiovascular and cerebrovascular events. During follow-up for participants in the intensive group, the sitting systolic pressure should be decreased to below 120 mm Hg, by titration and combination of the study medications of an angiotensin type-1 receptor blocker Allisartan (240 mg\u002Fday), a dihydropyridine calcium-channel blocker (amlodipine 5-10 mg\u002Fday), and\u002For other medications if necessary. For those in the standard group, the sitting systolic pressure should be monitored and controlled below 140 mm Hg.",[424,425,170,426,28],"Diabetes Mellitus, Type 2","Adverse Event","Prehypertension","2025-03-10",{"date":429,"type":39},"2025-03-12",{"date":431,"type":39},"2018-02-01",{"date":433,"type":21},"2025-09",{"name":435,"class":46},"XueQing Yu",{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":16,"sex":17,"minAge":444,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":22,"phases":447,"briefSummary":448,"conditions":449,"keywords":451,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":462,"leadSponsor":464,"locationsCount":47},"100436347","a-combined-multidomain-intervention-to-prevent-cognitive-decline-associated-with-cardiovascular-risk-factors-100436347","NCT04962061","A Combined Multidomain Intervention to Prevent Cognitive Decline Associated With Cardiovascular Risk Factors.","Impacts of Aerobic, Resistance and Cognitive Training Interventions on Neurocognitive Functions in Older Adults With Cardiovascular Risk Factors.","ACTIONcR","Inclusion Criteria:\n\n* Adult aged 60 and older,\n* Normal or corrected vision and normal hearing for their age range,\n* No cognitive impairment (Mini-Mental State Examination - MMSE ≥ 25),\n* Inactive (\\\u003C 150 min of physical activity per week).\n\nExclusion Criteria:\n\n* MMSE ≤ 24 or diagnosis of dementia,\n* Uncontrolled psychological \u002F psychiatric condition within the past 6 months,\n* Neurological disease,\n* Severe exercise intolerance,\n* Respiratory disease (e.g., asthma, COPD),\n* Excessive alcohol consumption (\\> 15 drinks\u002Fweek),\n* Documented cerebral, peripheral or coronary atherosclerotic disease,\n* Chronic systolic or diastolic heart failure,\n* Symptomatic aortic stenosis,\n* Atrial fibrillation,\n* Automatic implantable defibrillator or permanent pacemaker,\n* Malignant exertional arrhythmias,\n* Non-cardiopulmonary limitation to exercise (e.g., arthritis).","60 Years",{"count":446,"type":21},159,[24],"The ACTIONcardioRisk trial is designed to investigate the effect of aerobic and progressive resistance training exercises combined with cognitive training, on neurocognitive functioning of sedentary older adults with and without cardiovascular risk factors.",[450,28],"Aging",[450,452,453,454,455,456,457,118],"Cardiovascular Risk factor","Cognition","Combined Intervention","Cognitive Training","Physical Exercise","Brain Functions","2025-02-04",{"date":460,"type":39},"2025-02-06",{"date":225,"type":39},{"date":463,"type":21},"2025-12-31",{"name":465,"class":46},"Louis Bherer",{"id":467,"slug":468,"hasResults":11,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":473,"enrollmentInfo":474,"targetDuration":4,"studyType":22,"phases":476,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":47},"100533417","phase-2-lumasiran-in-hyperoxalaemic-patients-on-haemodialysis-100533417","NCT06225544","Lumasiran in Hyperoxalaemic Patients on Haemodialysis","LHOxH","Inclusion Criteria:\n\n* Male or female patients\n* Aged between 18 and 80 years old at the start of the study.\n* Women of child-bearing potential to consent to either abstinence or the use of contraception during the study period\n* Patients must have capacity to give written, informed consent to participate in the study prior to commencing the study. They must be fully aware of the aims, nature, planned interventions and potential risks of participating in the study. This consent must be obtained by the time of participant inclusion.\n* Established and stable on haemodialysis for at least 2 months\n* Thrice weekly haemodialysis\n* In possession of permanent dialysis access - either arterio-venous fistula (AVF) or graft (AVG) or permanent dialysis catheter\u002Ftunnelled haemodialysis line (THL).\n* ESKD not caused by previously diagnosed primary hyperoxaluria.\n* Mean baseline serum oxalate level of ≥20 μmol\u002FL\n* No recent (within last 2 months) significant changes to regular medications or diet\n\nExclusion Criteria:\n\n* Known diagnosis of PH1, 2 or 3; or a pathological mutation documented to cause primary hyperoxaluria.\n* Established on haemodialysis for less than 2 months.\n* On peritoneal dialysis.\n* Combined haemodialysis and peritoneal dialysis.\n* Temporary or poorly functioning haemodialysis access\n* Pregnancy, planning pregnancy or currently breast feeding.\n* Co-morbidity of an enteric disorder such as Inflammatory Bowel Disease (IBD), short gut syndrome, or a malabsorptive disorder.\n* Decompensated Liver failure.\n* Intercurrent active infection and\u002For antibiotic treatment.\n* Currently on Vitamin C treatment with a daily dose of more than 250mg.\n* Terminal illness and\u002For life expectancy of less than 1 year.\n* Currently relapsed or uncontrolled and symptomatic psychiatric disorder preventing compliance with the study.\n* Participants institutionalised by court or government order.\n* Patients who could be coerced due to dependency on the sponsor, the investigator, the trial sites or test centres.\n* Deranged liver function tests: If alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is more than twice the upper limit","80 Years",{"count":475,"type":21},50,[139],"This study will look at how well a drug that reduced the amount of oxalate in the body works in patients that have kidney disease and need dialysis treatment. People with kidney disease often have higher levels of oxalate in the blood. People with kidney disease are also at higher risk of having heart attacks, heart disease and strokes (these are called cardiovascular diseases). It is thought that high oxalate levels may increase the risk of these diseases. This study will investigate if this medicine can lower the amount of oxalate in the blood of dialysis patients and see if there is any change in the health of their heart. This medicine is already used for people who have high oxalate levels because of a genetic cause and has been used safely for patients on dialysis.\n\nThe study will put the participants randomly into either the group getting the study medicine or the group getting a placebo (this will be a solution of saline water). Neither participants not the doctors will know whether the drug or placebo is given until after the end of the study.\n\nAt the start of the study all the participants will have an echocardiogram (an ultrasound of the heart) and again 6 months later at the end of the study. We will also take blood tests once a month when the participants come for dialysis.",[479,480,481,28,482],"Haemodialysis","Chronic Kidney Disease Requiring Chronic Dialysis","Cardiovascular Disease","Hyperoxalemia","2024-08-19",{"date":485,"type":39},"2024-08-21",{"date":487,"type":39},"2024-04-14",{"date":489,"type":21},"2025-03-01",{"name":491,"class":46},"Charite University, Berlin, Germany",{"id":493,"slug":494,"hasResults":11,"nctId":495,"briefTitle":496,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":499,"targetDuration":274,"studyType":57,"phases":4,"briefSummary":501,"conditions":502,"keywords":506,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":47},"100365631","cardiometabolic-risk-factors-registry-100365631","NCT04040777","Cardiometabolic Risk Factors Registry","CARFARE","Inclusion Criteria:\n\n* Age \\>18 years old.\n\nExclusion Criteria:\n\n* Previous cardiovascular and\u002For cerebrovascular event\n* stable chronic angina\n* advanced chronic kidney disease (Stage IV or V)\n* cancer",{"count":500,"type":21},25000,"CARFARE (CARDIOMETABOLIC RISK FACTORS REGISTRY) is a registry done in the context of a cardiovascular primary prevention program of the Cardiometabolic Unit Officia of the Cardiology Department of the Austral University Hospital. The structured and sequential evaluation include measurement of anthropometric parameters (body mass index, BMI), laboratory with metabolic profile, baseline electrocardiogram, blood pressure (BP) measurement, arterial stiffness, subclinical atherosclerosis screening in the carotid and ileo-femoral territories using echo-doppler, echocardiogram, and ergometry test.",[503,504,394,28,60,505],"Atherosclerosis","Metabolic Syndrome","Obesity",[507,504,508],"Subclinical Atherosclerosis","Primary Prevention","2024-06-08",{"date":511,"type":39},"2024-06-11",{"date":513,"type":39},"2015-06",{"date":515,"type":21},"2030-12",{"name":517,"class":46},"Austral University, Argentina",{"id":519,"slug":520,"hasResults":11,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":11,"sex":17,"minAge":525,"maxAge":526,"enrollmentInfo":527,"targetDuration":528,"studyType":57,"phases":4,"briefSummary":529,"conditions":530,"keywords":539,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":47},"100544681","tornado-omics-techniques-and-neural-networks-for-the-development-of-predictive-risk-models-100544681","NCT06372054","TORNADO-Omics Techniques and Neural Networks for the Development of Predictive Risk Models","Integration of Omics-based Technologies and Artificial Intelligence to Identify Predictive Risk Models in a Air Force's Pilot Cohort for the Maintenance of Safety, Well-being, Health, and Performance to be Translated to Civil Population","Inclusion Criteria:\n\n* Being part of the Italian Air Force, as in active flight service or ground staff\n* Age between 26 and 38 years\n* Consent to collect biological samples and use the wearable device to monitor exposure parameters\n\nExclusion Criteria:\n\n* Age \\\u003C 25 years and \\> 39 years\n* no signature on informed consent","26 Years","38 Years",{"count":386,"type":21},"3 Years","The goal of this observational study is to define a personalized risk model in the super healthy and homogeneous population of Italian Air Force high-performance pilots. This peculiar cohort conducts dynamic activities in an extreme environment, compared to a population of military people not involved in flight activity. The study integrates the analyses of biological samples (urine, blood, and saliva), clinical records, and occupational data collected at different time points and analyzed by omic-based approaches supported by Artificial Intelligence. Data resulting from the study will clarify many etiopathological mechanisms of diseases, allowing the creation of a model of analyses that can be extended to the civilian population and patient cohorts for the potentiation of precision and preventive medicine.",[531,532,533,28,534,535,536,537,538],"Oxidative Injury","Stress Physiological","Discogenic Pain","Space Maintenance","Epigenetic Changes","LONGEVITY 1","Neuroplasticity","NGS",[540,541,542,543],"pilots","air force","epigenetic change","environmental exposure","2024-04-16",{"date":546,"type":39},"2024-04-17",{"date":548,"type":39},"2024-02-05",{"date":550,"type":21},"2027-02-05",{"name":552,"class":46},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":554,"slug":555,"hasResults":11,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":11,"sex":324,"minAge":561,"maxAge":4,"enrollmentInfo":562,"targetDuration":274,"studyType":57,"phases":4,"briefSummary":563,"conditions":564,"keywords":567,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":47},"100357753","womens-advanced-risk-assessment-in-manitoba-100357753","NCT03938155","Women's Advanced Risk-assessment in Manitoba","Women's Advanced Risk-assessment in Manitoba (WARM) Hearts - Examining Cardiovascular Disease Risk in Middle Aged and Older Women","WARM","Inclusion Criteria:\n\n* women aged 55 and older\n* possess a Manitoba Personal Health Information Number\n\nExclusion Criteria:\n\nPrevious hospitalization or treatment for:\n\n* Ischemic heart disease\n* Acute myocardial infarction\n* Stroke\u002FTransient ischemic attack\n* Percutaneous coronary intervention\n* Coronary artery bypass surgery\n* Congestive heart failure\n* Peripheral artery disease\n* Congenital heart defects\n* Arrhythmia\n\nAdditional exclusion:\n\n* Medical advice against physical activity\n* Previous participant in the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease (NCT02863211)","55 Years",{"count":191,"type":21},"The main objective of this study is to test the ability of novel cardiovascular disease (CVD) prognostic tools to identify women at risk for future CVD. We plan to establish a cardiovascular health screening program at the St. Boniface Hospital and to test the efficacy of these tests for predicting adverse cardiovascular outcomes amongst a cohort of 1000 Manitoban women aged 55 years and older in the 5-year period after screening.\n\nA second purpose of this project is to identify novel CVD biomarkers that may indicate a person is at risk for cardiovascular disease. Therefore, we plan to ask participants for permission to collect and store a sample of both their blood and stool for future research.",[565,28,566],"Cardiovascular Disease (CVD)","Vascular Stiffness",[568,569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592,593],"female","humans","aged","cardiovascular system","cardiovascular diseases","cardiovascular diseases\u002Fepidemiology","early diagnosis","frailty","frailty elderly","prospective studies","Manitoba\u002Fepidemiology","gastrointestinal microbiome","cohort studies","cause of death","risk assessment","biomarkers","risk factors","pulse wave analysis","accelerometry","exercise","physical fitness","gender","sex","women","early detection","screening program","2021-01-25",{"date":596,"type":39},"2021-01-28",{"date":598,"type":39},"2019-10-01",{"date":600,"type":21},"2026-10",{"name":602,"class":46},"St. Boniface Hospital",{"id":604,"slug":605,"hasResults":11,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":609,"eligibilityCriteria":610,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":473,"enrollmentInfo":611,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":613,"conditions":614,"keywords":617,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":47},"100365292","liver-damage-and-cardiometabolic-disorders-in-nafld-100365292","NCT04036357","Liver Damage and Cardiometabolic Disorders in NAFLD","Progression of LIver Damage and Cardiometabolic Disorders in Non-alcoholic Fatty Liver dIsease: an Observational Cohort STUDY. The Plinio Study","PLINIO","Inclusion Criteria:\n\n* Patients aged 18 years old or more\n* Patients with at least on of the following metabolic disorders\n\n  * Obesity\n  * Diabetes\n  * Arterial hypertension\n  * Dyslipidemia\n\nExclusion Criteria:\n\n* Average daily consumption of alcohol \\>20 g in women and of \\>30 g in men (assessed by Alcohol Use Disorders Identification Test, AUDIT;\n* presence of hepatitis B surface antigen and antibody to hepatitis C virus;\n* positive tests for autoimmune hepatitis;\n* cirrhosis and other chronic liver diseases;\n* diagnosis of oncological diseases\n* concomitant therapy with drugs known to promote liver steatosis (e.g. amiodarone);\n* other chronic infectious or autoimmune disease;",{"count":612,"type":21},2000,"Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.",[615,616,60,28],"NAFLD","Liver Fibroses",[615,618,619],"Liver fibrosis","Cardiovascular","2019-08-13",{"date":622,"type":39},"2019-08-16",{"date":624,"type":39},"2011-11",{"date":626,"type":21},"2036-12-31",{"name":628,"class":46},"University of Roma La Sapienza"]